Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cloudflare Inc (NET) vs BIO-TECHNE Corp (TECH) Price & Performance

Cloudflare IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Cloudflare Inc vs BIO-TECHNE Corp — how do they compare? Cloudflare Inc trades at $346.6 (market cap $121.74B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Cloudflare Inc is far larger — about 10.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and BIO-TECHNE Corp for 63 Days on average.

NETTECH
Market Cap
$121.74B$11.36B
Volume
2,433,0025,390,331
Sector
TechnologyHealth
52-Week High
$359.60$72.61
52-Week Low
$160.16$43.31
Typical Hold Time
61 Days63 Days
Enterprise Value
$121.11B$11.39B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cloudflare Inc

Cloudflare (NET) trades at $342.82, down 3.44% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with $2.17 billion in 2025 sales, though profitability remains challenged with a -8.21% net margin. Recent technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains overwhelmingly positive with 71% buy ratings. The company's recent product launches including Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight ongoing innovation in the connectivity cloud space.

Cloudflare presents a growth story with expanding enterprise adoption but faces valuation concerns at current levels. The stock's premium multiples (P/S 47.88) require continued execution against strong revenue growth targets. Key risks include persistent profitability challenges and competitive pressures in the cloud security market, while catalysts include AI-driven security demand and platform consolidation opportunities.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NET
61% Buy39% Sell
Avg holding period · 61 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Cloudflare Inc

Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.

Read more on NET →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →